Keywords
HIV, quality of care, variation, Public Health
HIV, quality of care, variation, Public Health
In addition to choice of appropriate drugs, best practice management of patients with HIV requires monitoring response to treatment and disease progression. This includes tracking clinical immunological, and virological data on patients at diagnosis and on follow-up. There is a rich literature guiding HIV treatment, and guidelines are developed and updated regularly as new evidence comes to light1–5 (see http://www.who.int/hiv/pub/guidelines/en/ for an historic list of guidelines produced by the World Health Organisation). The implementation of standardized protocols for treatment and investigations may vary in resource constrained countries, with differences in resources available for such services. For example, the current guidelines for antiretroviral therapy (ART) requires all patients on ART to have viral load test at six months and 12 months5, implementation might vary based on availability of resources to support viral load testing. While a number of reports of current treatment and testing practice are available from resource-limited settings, these are mainly in the context of patients enrolled in research centres or in research studies6–8. Such settings often have substantially more resources than routine clinical practices, and as such practice patterns may differ from routine practice, where issues such as clinic and patient resources or drug stock-outs can affect care. This study was designed to explore variation in the evaluation, treatment, care and follow-up among patients diagnosed with HIV in routine care settings in low- to middle-income countries.
Interest in participating in this study was sought among the Masters of Public Health Alumni of Peoples-uni9. A protocol was developed by those who responded (Supplementary File 1), and a retrospective cohort was created via standardized record review.
A data collection instrument was developed, based on previous research and publications and management guidelines1–5. A spreadsheet was created with coding instructions (Supplementary File 2). In addition, data on the characteristics of the setting for each facility were collected in early 2017 by each investigator in consultation with local clinic staff, and entered onto an online survey form (Supplementary File 3). This included country and city, hospital or other healthcare facility, number of patients seen, and what diagnostic, treatment, referral and follow-up facilities are available. Clinic and patient data were de-identified to maintain confidentiality. Four clinics from three countries in sub-Saharan Africa chose to participate in the study.
For clinic BA, a public hospital clinic in northern Nigeria, patients were selected in sequence of attendance as new patients, starting January 1, 2013 for whom records were also available over the next two years. Patient demographics were those obtained at the first visit, and CD4 count and ART treatments were recorded at each visit, with analysis relating to data recorded at the most recent visit.
For clinic EV, a public hospital clinic also in Nigeria, all existing patients were re-tested with an ELISA method in 2013/14, and patients were randomly selected for this study among those who tested positive at that time. CD4 count and treatments recorded were those at the latest visit, and patient demographics were those in the records from their first visit.
For clinic MW, a public community-based clinic in Zambia, patients were randomly selected from those present on the patient registry in 2015/16. At that time, patients were reviewed for the need to start on highly active antiretroviral therapy (HAART) based on CD4 count, and the ART regime recorded was that started as a result of that review at that time. Data on patient demographics were those present in the records, often this would be prior to the date of entry to this study.
For clinic AM, a public hospital based clinic in Uganda, the sampling frame was the register of all clients on active ART, and every third patient file was retrieved from files ordered according to clinic appointment date. The CD4 counts and ART regimes recorded were for the most recent measures in the records, and patient demographics were those in the records from their first visit.
Data on individual patients were extracted from medical records, including age, gender, and baseline clinical data at diagnosis and follow-up. Clinical information included clinical, immunological and virological information on patients at diagnosis and on follow-up, prescription of ART and other drug choices, important co-infections and/or co-morbidities.
Details of the tests ordered and their results, and treatments ordered were extracted from medical records. Individual patients were not contacted. Data were obtained from the records, and no attempt was made to validate the information. Missing data were recorded as missing, and not explored further.
A pilot study tested the feasibility of the data collection and the method of recording on to a spreadsheet. Data were collected by a research assistant in each setting, using the spreadsheet, from examination of individual records.
As a retrospective patient records study, consent was not requested from individual patients. Ethics approval was sought and obtained in each setting from the appropriate authority (see Ethical approval and consent section). Considerable care was taken not to reveal the identity of any individual and all data were de-identified. The spreadsheet for the recording of data only had an identification number, and the key to the identity of each patient was kept separately to maintain confidentiality. To further this, the clinics names and exact locations have been removed.
Descriptive statistics were used to characterise the study population. Data distributions were assessed, checking for skewness and kurtosis. Data summary statistics were generated. Categorical variables were summarized using proportions while continuous variables were summarized using medians and interquartile ranges. Due to differences in data extraction across sites, no statistical analyses comparing across sites was conducted. All analyses were conducted in Stata 14.1 (StataCorp, College Station, X) and R version 3.3.0 (The R Foundation for Statistical Computing).
Ten alumni expressed interest in participating, three centres were able to pilot the data collection instrument and four centres in three countries participated in the data collection for the study. Overall, data were abstracted for 600 patients.
Table 1 shows the characteristics of the 4 clinics. The number of patients seen per month varied from 500 to 4200, and the number of doctors, nurses, and allied health professionals available at the clinics varied from 1 to 50, 10 to 65, and 6 to 45 respectively. There was some variation in the stated frequency of testing for CD4 count (either every three or six months) and for measurement of viral load. Each clinic had availability of clinical guidelines, and most drugs were available free of charge to patients. All clinics have access to ART and co-trimoxazole.
Table 2 shows the patient characteristics and test results. Age, gender and body mass index (BMI) were similar between clinics, with overall median age of 31 years, 62% were female and median BMI was 20. The proportion of patients with a CD4 count in the records varied from 84 to 100 percent, and the latest median count varied from 269 to 593 between the clinics. 209 (35%) had a record of a viral load test with 81% of then having a viral load of less than 50 copies/µL. Only 23 (19%) of 119 patients had records of AIDS defining illnesses. Figure 1 shows the variation in the distribution of the CD4 counts in each of the four clinics.
BA (N=100) | EV (N=100) | MW (N=100) | AM (N=300) | Overall (N=600) | |
---|---|---|---|---|---|
Age (median, IQR) | 32 (28 to 40) | 28 (21 to 37) | 33 (29 to 39) | 31 (23.5 to 38) | 31 (24 to 38) |
Female sex | 57 (57.6%) | 62 (62.0%) | 55 (55.6%) | 197 (65.7%) | 371 (62.0%) |
BMI at presentation1 | 22.8 (19.5 to 31.2) | No data | 19.5 (17.9 to 21.8) | 20.0 (18.3 to 22.2) | 20.0 (18.2 to 22.3) |
Number of patients w/CD4 count data | 100 | 94 (94%) | 84 (84%) | 279 (93%) | 558 (93%) |
Latest CD4 Count (median, IQR) | 269 (177 to 461) | 593 (390 to 880) | 307 (169.5 to 471.5) | 499 (321 to 691) | 436.5 (267 to 471.5) |
Proportion of patients w/viral load | 14 (14%) | 6 (6%) | 1 (1%) | 188 (62.7%) | 209 (34.8%) |
Latest viral load <50 50-9,999 10,000-99,999 >99,999 | 6 (43%) 1 (7%) 3 (21%) 4 (29%) | 2 (33%) 4 (67%) 0 0 | 1 (100%) 0 0 0 | 160 (85%) 0 28 (15%) 0 | 169 (81%) 5 (2%) 31 (15%) 4 (2%) |
AIDS defining illness | 2/2 | 7/21 | 14/96 | No data | 23/119(19%) |
Table 3 shows the treatment regimes. Lamivudine (3TC) was recorded for more than 90% of patients in each clinic, but otherwise there was considerable variation between clinics in the choice of ART. Tenofovir disoproxil fumarate (TDF) was prescribed for 317 (53.9%) of studied patients. Efavirenz (EFV) was prescribed for 326 (55%) of the patients, making combination of TDF/3TC/EFV the most common ART combination used by studied patients. In two clinics, 100% and 99% of patients were prescribed co-trimoxazole prophlaxis, compared with 7% and no patients in the two other clinics. There were 6 patients on lopinavir and 8 on atazanavir (second line treatment choices).
Data were collected in a standardised way, with data on treatment regimes and CD4 counts relating to the latest information in the records (dates ranging from 2015 to 2017). While we initially planned to collect data on a cohort of patients enrolled two years before data collection in each clinic, this did not prove feasible and patients had presented to the clinics at variable times.
This study found modest documentation of clinical activities, with a wide variation in available clinic health work force, frequency of CD4 counts and levels and viral load assessment. While most patients had a CD4 count in the records, there was a wide spread of latest CD4 counts, with both within- and between-centre variation in the CD4 counts. Only one in three patients had a record of viral load at any time during the course of treatment, and most of these had an undetectable level (<50 copies/µL). Some of the absence of viral load might be poor record keeping, and the high proportion of undetectable results might reflect an absent rather than a low test result, and hence not an indicator of treatment success. Over the years the CD4 threshold for commencing ART had been lowered, as can be seen in Table 4, with the most current guideline requiring a “test and treat approach” ie eliminating CD4 threshold as a prerequisite for commencement of ART5. While this guideline is based on sound evidence, it adds an unanticipated number of potential eligible patients for ART care, with attendant strain on countries with an already fragile economy. The low frequency of viral load test results might also reflect resource limitations.
When to start ART in adults | ||
---|---|---|
TIME | REFERENCE | RECOMMENDATION |
2002 | Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach1 http://www.who.int/hiv/pub/guidelines/pub18/en/ | ART treatment if: • CD4 <200 cells/mm3 WHO stage I, II, or III OR • WHO Stage IV AIDS-defining illness, irrespective of CD4 count • First line therapy ZDV/3TC/EFZ or ZDV/3TC/NVP |
2006 | Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2006 revision)2 http://www.who.int/hiv/pub/arv/adult/en/ | • All adolescents and adults including pregnant women with HIV infection and CD4 counts of ≤200 cells/mm3, should start ART, • First line treatment NRTI AZT or TDF combined with either 3TC or FTC; NNRTI, either EFV or NVP, should be added |
2010 | Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision3 http://www.who.int/hiv/pub/arv/adult2010/en/ | • All adolescents and adults including pregnant women with HIV infection and CD4 counts of ≤350 cells/mm3, should start ART, • First-line therapy should consist of an NNRTI + two NRTIs, one of which should be AZT or TDF • Second-line ART should consist of a ritonavir-boosted protease inhibitor (PI) plus two NRTIs, one of which should be AZT or TDF • Irrespective of CD4 cell counts, patients coinfected with HIV and TB should be started on ART • Irrespective of CD4 cell counts or WHO clinical stage, patients who require treatment for HBV infection should start ART. |
2013 | Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach4 http://www.who.int/hiv/pub/guidelines/arv2013/download/en/ | • As a priority, ART should be initiated in all individuals with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) and individuals with CD4 count ≤350 cells/mm3 • ART should be initiated in all individuals with HIV with CD4 count >350 cells/mm³ and ≤500 cells/mm3 regardless of WHO clinical stage • ART should be initiated in all individuals with HIV regardless of WHO clinical stage or CD4 cell count in the following situations: • Individuals with HIV and active TB disease (strong recommendation, low-quality evidence). • Individuals coinfected with HIV and HBV with evidence of severe chronic liver disease • Partners with HIV in serodiscordant couples should be offered ART to reduce HIV transmission to uninfected partners (strong |
2015/6 | Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach - Second edition5. http://www.who.int/hiv/pub/arv/arv-2016/en/ | • Retesting prior to enrollment in care ART should be initiated in all adults living with HIV, regardless of WHO clinical stage and at any CD4 cell count • As a priority, ART should be initiated in all adults with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) and adults with a CD4 count ≤350 cells/mm3 • ART should be started in all TB patients living with HIV regardless of CD4 count • Preferred first line ART regimen TDF + 3TC (or FTC) + EFV • Combinations of ATV and LPV are the preferred boosted PI options for second-line ART • Routine viral load monitoring can be carried out at 6 months, at 12 months and then every 12 months thereafter if the patient is stable on ART to synchronize with routine monitoring and evaluation reporting • CD4 count every 6 months until in settings where routine viral load monitoring is available, until are stable on ART • Viral load is recommended as the preferred monitoring approach to diagnose and confirm treatment failure |
Most patients were on TDF/3TC/EFV drug regimen, which is consistent with current guideline advice for first line treatment. Only 2% of the patients were on second-line ART, varying from 9% to less than 1% between clinics. It is likely that most of the studied patients are still on a potent first line ART judging by the low second-line ART usage. Use of a regimen with a low pill burden would enhance therapy adherence and might lead to reduced need for switching patients to second line ART10. TDF/3TC/EFV drug regimens have a low pill burden, and may contribute to the low usage of second-line ART regimens.
The variation in the use of co-trimoxazole, from almost universal in two clinics, to negligible in the other two clinics, is an extreme example of the variation we identified. The reason for this variation despite the guideline recommendation is not clear, but it is possible that it is a result of local clinic policy settings, possibly related to concerns about increasing antibiotic resistance. Variation in the use of co-trimoxazole has been found in other resource-limited settings, while efforts are being made to improve the rates of use11.
While each clinic reported having access to treatment guidelines, those current at the time of the data collection do not appear to have been universally followed. The guidelines also do change regularly, as shown in Table 4. For example in relation to the frequency of CD4 count monitoring and the CD4 count threshold at which treatment should be started have changed since the time relating to the study data - new guidelines recommend starting treatment regardless of the CD4 count5,12. Some discrepancy between WHO guidelines and actual implementation in practice may arise from the time it takes to implement new guidelines, or due to lack of resources to immediately initiate all patients with HIV on ART. We see considerable between-clinic variation in a number of key management strategies reported by the clinics, from the recording of CD4 counts, median CD4 counts on treatment, and treatments used. This variation is consistent with a previous survey of stated management practices in 6 sub-Saharan countries13,14.
The management of patients in routine clinical care has been shown to differ from that seen in clinical trials15, as well as to lead to worse clinical outcomes, although it is beyond the scope of our study to explore outcomes. Findings of variation from standard management practice has previously been reported from routine care settings in other parts of sub-Saharan Africa including Ethiopia16, Uganda17 and Tanzania18, mostly in single isolated centres. Here we present combined data on health system related measures across multiple sub-Saharan African HIV treatment sites.
In the absence of standardised record keeping systems, it is difficult to make clear comparisons of management and outcome in routine clinical care. Our findings suggest that there is room for further work to understand the reasons for these record gaps, and to standardise the record keeping in routine care of HIV positive patients. The potential of electronic medical records to improve records could be explored.
Our study has a number of limitations. First, this study was an analysis of data extracted from existing medical records, which are prone to error including missing data. We have found missing data where it should ordinarily not be missing. We cannot comment on other factors that may have contributed to missing data, such as whether tests were not done or if they were not recorded. Second some of the variation between centres may be due to differences in patient populations which we were unable to capture, even though we selected clinics involved in routine clinical care. Third, participation in the study was restricted to few countries, and to individual clinics, which may not be representative of the national picture in these countries. A prospective cohort study on representative samples would provide a more robust study design with more detailed quantitative data to delineate care dynamics and to explore clinical outcomes.
We demonstrate a wide variability in compliance with HIV treatment guidelines in four settings in sub-Saharan Africa, as well as gaps in the records available. The findings of this study may provide an explanation for heterogeneous HIV treatment outcomes across sub-Saharan Africa. In spite of the limitations, these data underscore the need for an in-depth study to address compliance with HIV treatment guidelines and best practice. While electronic medical record implementation might be a challenge for many HIV care points in sub-Saharan Africa, our findings emphasize the need for more robust interim paper-based medical record keeping.
Ethics approval was sought in each setting from the appropriate authority. For two of the centres, research ethics committees gave approval. In two of the centres, the ethics committees stated that they did not require formal approval from them, however approval to access records was obtained from the relevant District Health Office/r. Details for each clinic as follows:
Clinic BA: Ethics approval obtained from Aminu Kano Teaching Hospital Research Ethics Committee.
Clinic EV: Ethics approval obtained from Research and Ethics Committee of State House Medical Centre, Abuja.
Clinic MW: University of Zambia Biomedical Research Ethics Committee contacted and advised to notify the Lusaka District Health Office (LDHO) who gave approval.
Clinic AM: Eastern Uganda AIDS Support Organization (TASO) contacted who recommended no need for an approval but rather write to the Amuria District Health Officer (DHO) for permission to have access to the hospital records, which was given.
Informed consent was not obtained from individual patients since this was a records study with appropriate institutional approval, strict confidentiality arrangements, and no patient contact, as stated in the manuscript.
Dataset 1. De-identified data collected from clinical records used to create Table 2 and Table 3 and Figure 1. Scheme used to code the data is available as Supplementary File 2. 10.5256/f1000research.15169.d20633319
All data underlying the survey responses from clinic informants for Table 1 are available as part of the article.
Thanks to Rebecca Oyomopito for help with designing the data collection instrument, Ado Abubakar for help with piloting the instrument, and Krishna Shrinivas for help through Statistics Without Borders.
Supplementary File 1 – Study protocol
Click here to access the data.
Supplementary File 2 – Data coding scheme
Click here to access the data.
Supplementary File 3 – Written from of online survey
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
No source data required
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
No
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Epidemiology, regression modelling, pathogen genomics
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 3 (revision) 04 Jan 19 |
|||
Version 2 (revision) 26 Sep 18 |
read | read | read |
Version 1 08 Jun 18 |
read | read |
Click here to access the data.
Spreadsheet data files may not format correctly if your computer is using different default delimiters (symbols used to separate values into separate cells) - a spreadsheet created in one region is sometimes misinterpreted by computers in other regions. You can change the regional settings on your computer so that the spreadsheet can be interpreted correctly.
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)